Funding for this research was provided by:
National Cancer Institute (P50 CA142509)
International Waldenstrom's Macroglobulinemia Foundation
Received: 9 June 2017
Accepted: 5 February 2018
First Online: 13 February 2018
Ethics approval and consent to participate
: This study will be conducted according to the ethical principles for medical research involving human subjects as stated in the Declaration of Helsinki and in the ICH Good Clinical Practice guidelines. The study protocol has been reviewed and approved by the Institutional Review Board of the University of Texas M.D. Anderson Cancer Center (reference number 2009-0465). All eligible participants will have the study, timelines, and outcome measures of the study explained to them. Participants will be informed that they are free to discontinue participation at any time without consequence. To indicate consent, the participant will sign the written informed consent form.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.